Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand

Acta Pharmacologica Sinica

Volumn 26, Issue 11, 2005, Pages 1373-1381

  Fang, Fang ^a   Wang, Ai Ping ^a   Yang, Shi Fang ^b  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b Beijing Sunbio Biotech Co Ltd   (China)

Author keywords

Antineoplastic agents; Apoptosis; Flow cytometry; NCI H460 cells; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

ANNEXIN; DNA FRAGMENT; RECOMBINANT MUTANT HUMAN TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL STRAIN COLO205; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CELL STRAIN NCI H460; CELL STRAIN QG 56; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SAFETY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL; LUNG FIBROBLAST; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; SKIN FIBROBLAST; TUMOR CELL LINE; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 27744591250     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00206.x     Document Type: Article

References (26)

1. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997; 88: 347-54.
2. Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445-9.
3. Wyllie AH. Apoptosis: cell death in tissue regulation. J Pathol 1987; 153: 313-6.
4. Moriya N, Miwa H, Orita K. Antitumor effects of bacterial lipopolysaccharide and tumor necrosis factor in mice. Jpn J Surg 1984; 14: 163-6.
5. Ishida Y, Kondo T, Tsuneyama K, Lu P, Takayasu T, Mukaida N. The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice. J Leukoc Biol 2004; 75: 59-67.
6. Lombard C, McKallip RJ, Hylemon PB, Nagarkatti PS, Nagarkatti M. Fas ligand-dependent and -independent mechanisms of toxicity induced by T cell lymphomas in lymphoid organs and in the liver. Clin Immunol 2003; 109: 144-53.
7. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Jillian K, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-82.
8. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenzai A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-90.
9. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-62.
10. Kelley SK, Harris LA, Xie D, DeForge L, Totpal K, Bussiere J, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299: 31-8.
11. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-63.
12. Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002; 9: 164-72.
13. Yoshida S, Narita T, Koshida S, Ohta S, Takeuchi Y. TRAIL/ Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines. Pediatr Res 2003; 54: 709-17.
14. Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S, Evdokiou A. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer 2003; 89: 206-14.
15. Frese S, Brunner T, Gugger M, Uduehi A, Schmid RA. Enhancement of Apo2L/TRAIL(tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg 2002; 123: 168-74.
16. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-inducing apoptosis. Int J Cancer 2002; 99: 491-504.
17. Mariani SM, Matiba B, Armandola EA, Krammer PH. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol 1997; 137: 221-9.
18. Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A, et al. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol 1996; 6: 750-2.
19. Wand WR. In vivo methods. In: Teicher BA, editor. Anticancer drug development guide, preclinical screening, clinical trials, and approval. Humana Press: Totowa NJ; 1997. p59-213.
20. Aragane YD, Kulms D, Metza D, Wilkes G, Poppelman B, Luger TA, et al. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/Apo-1) independently of its ligand CD95L. J Cell Biol 1998; 140: 171-82
21. Hymowitz SG, O'Connell MP, Ultsch MA, Hurst A, Totpal K, Ashkenzai A, et al. A unique zinc-binding site revealed by a high-resolution x-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000; 39: 633-40.
22. Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, et al. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003; 63: 2369-72.
23. Mundt B, Kuhnel F, Zender L, Paul Y, Tillmann H, Trautwein C, et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 2003; 17: 94-6.
24. Roth W, Isenman S, Naumann U, Kugler S, Bahr M, Dichgans JA, et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999; 265: 479-83.
25. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/ TRAIL versions. Nat Med 2001; 7: 383-5.
26. Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001; 3: 535-46.